Investing.com -- Shares of pharmaceutical giant Merck & Co ., Inc. (NYSE:MRK) edged up 1.6% in premarket trading following news of a significant licensing agreement with Chinese biotech firm Hansoh Pharmaceutical (TADAWUL:2070) Group Company Limited (3692.HK). The deal centers on the experimental obesity drug HS-10535, for which Merck (NS:PROR) will pay Hansoh an upfront sum of $112 million, with potential milestone payments totaling up to $1.9 billion.
As part of the arrangement, Merck will record a charge of $112 million before taxes in the fourth quarter of 2024. The collaboration with Hansoh Pharma marks a strategic move for Merck to expand its portfolio in the treatment of obesity, a growing global health concern.
The financial terms of the deal reflect the potential Merck sees in HS-10535, which is still in the experimental phase. The upfront payment and subsequent milestone payments are indicative of the company's commitment to advancing its research and development pipeline in a therapeutic area with significant unmet medical needs.
While the charge in Q4 2024 will impact Merck's financials, the long-term prospects of the HS-10535 drug could offer substantial returns should the treatment prove successful in clinical trials and eventually gain market approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.